Business Wire

Shippeo Introduces Carbon Visibility and Brings Powerful New Features to Ocean and Road Visibility

9.5.2022 13:28:00 EEST | Business Wire | Press release

Share

Shippeo, a leading provider of global and multimodal shipment visibility, today announced new products and major platform enhancements, as part of their feature-packed 2022 Spring platform release. The updates focus on customer satisfaction, new innovations, performance, and meeting evolving market needs. A new CO2 emissions calculator provides critical information on carbon emissions and other greenhouse gasses from supply chain transport and distribution for shippers, logistics service providers and carriers. Container tracking using Shippeo’s Ocean Visibility solution is now faster and easier with a new user experience and powerful monitoring capabilities. In addition, timesaving usability enhancements, data quality improvements and ETA accuracy advancements are introduced for the company’s market-leading Road Visibility product. Finally with the migration to Google Cloud and Snowflake, significant performance and scalability upgrades are added to the Shippeo platform.

“Our latest Spring platform release is packed full of new features and capabilities for customers,” explains Anand Medepalli, Chief Product Officer at Shippeo, “including a completely new Carbon Visibility offering for accurately calculating CO2 and other greenhouse gas emissions at the shipment level, as well as major enhancements to our Ocean and Road visibility solutions. We are evolving our platform to not only meet the needs of our customers today, but also to solve tomorrow’s supply chain problems. This is the first release in a new twice-yearly Spring and Autumn Shippeo platform release cycle, representing a shift to more regular and regimented platform updates. This reliability and momentum will help us to keep ahead and continue to offer the most innovative real-time visibility platform experience for users, more powerful capabilities to increase productivity, and higher data quality to improve ROI for our customers.”

Accurate, consolidated CO2 emissions monitoring for shippers and carriers
Carbon Visibility offers shippers and logistics service providers a consolidated view of CO2 emissions for upstream and downstream transport and distribution activities in one place, bringing a number of new capabilities to help companies monitor progress towards sustainability objectives.

Carriers also benefit from the new Carbon Visibility offering, allowing them to avoid the time consuming manual work that they are faced with today to calculate emissions on behalf of their clients. Carriers can now use Shippeo to instantly generate CO2 emission reports, which should allow them to more easily allocate CO2 emissions from a single vehicle to multiple customers in LTL/groupage scenarios based on their business rules.

The Shippeo Carbon calculator follows the GLEC framework and is compliant with EN 16258 and GHG protocol.

Advanced container tracking over ocean
Major enhancements to Ocean Visibility will help supply chain and transport managers track and manage container shipments more productively, with new features and a revamped user experience, including:

  • More detailed container event information with new AIS-based milestones and precise geofencing
  • A revamped order detail page displaying all relevant container tracking information
  • Ability to identify deviations from status information provided by ocean carriers
  • An updated global map providing a holistic view of ocean shipments, by vessel or individual container
  • New filters making searching for containers easier
  • Higher overall data quality with inputs from new data sources

Road tracking enhancements
Timesaving usability enhancements, data quality improvements and ETA accuracy advancements are introduced for Road Visibility , offering customers an even more powerful over-the-road shipment tracking solution.

  • ETA accuracy improves 32% thanks to AI/ML algorithm advancements, upgraded Dataiku ML Ops platform infrastructure and data science methodology advancements
  • Shuttle flow tracking enables better differentiation between shipments within multiple back-and-forth tours for more accurate departure and arrival times
  • Quality Newsletters notify users of data tracking rates and provides steps for improving tracking quality
  • Improved visibility and readability of information, with new tagged events and links between map and timeline views

Infrastructure improvements to boost data quality and user experience
Shippeo’s platform has been migrated to Google Cloud Platform in its entirety, representing a major improvement in infrastructure. The shift ensures significant scalability, performance and localization capabilities along with enhanced security for customers.

Alongside the platform feature additions and enhancements, Shippeo has also continued to double-down on higher data quality, an area in which the company consistently leads the market. Continued investment of significant capital into R&D aims to advance the platform’s AI/ML capabilities even further.

To that point, the data warehouse powering Shippeo Insights is now migrated to Snowflake, a state-of-the-art high-performance analytics database that has managed to reduce Shippeo dashboard loading times by 50% on average and up to 90% for large customers.

About Shippeo
Shippeo, a global leader and European specialist in real-time transportation visibility, helps major shippers and logistics service providers leverage transportation to deliver exceptional customer service and achieve operational excellence. Their Multimodal Visibility Network connects FTL, LTL, parcel, and container transport and integrates 875+ TMS, telematics and ELD systems using a unique API. The Shippeo platform provides instant access to real-time delivery tracking, automates customer processes and offers unmatched ETA accuracy thanks to a proprietary and industry-leading algorithm developed in-house. Hundreds of customers, including global brands like Coca-Cola HBC, Carrefour, Renault Group, Schneider Electric, Total, Faurecia, Saint-Gobain and Eckes Granini, trust Shippeo to track more than 28 million shipments per year across 75 countries. Learn more at www.shippeo.com

LinkedIn, Facebook, Twitter

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Europe: Andrea Krug, Krug Communications Ltd, Tel. +44 (0)7740 245 867, email: andrea@krugcomms.com

North America: Carol Kraeutler Lerner, CKL Communications, Tel. +1 (201) 602-7572, email: ckl.communications@gmail.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Azafaros to Present at BIO International Convention 202615.6.2026 08:00:00 EEST | Press release

Azafaros, a private company building a portfolio to become a leader in lysosomal storage disorders (LSDs), focused on addressing neurological symptoms, today announced that it will present at the 2026 BIO International Convention taking place in San Diego, USA, from June 22-25. The company’s presentation is scheduled for Monday, June 22 at 4:30 PM in Theater 4. The presentation will highlight Azafaros’ progress in developing nizubaglustat, its lead investigational compound for the treatment of rare lysosomal storage disorders with neurological involvement, including GM1 and GM2 gangliosidoses (GM1/GM2) and Niemann-Pick type C disease (NPC). Nizubaglustat is currently in two Phase 3 registrational studies (NAVIGATE) treating patients with GM1/GM2 and NPC and expects to report topline data from the studies in 2028. “BIO provides an important opportunity to update our progress as we continue advancing nizubaglustat through late-stage clinical development,” said Stefano Portolano, CEO at A

Teledyne FLIR Defense Launches Black Recon™ Autonomous Micro-Drone15.6.2026 07:05:00 EEST | Press release

Teledyne FLIR Defense, part of Teledyne Technologies Incorporated (NYSE: TDY), today announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone system that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260614388428/en/ Teledyne FLIR Defense announced at Eurosatory the market launch of Black Recon™, an autonomously launched micro-drone that delivers continuous, untethered reconnaissance from military vehicles and fixed installations. Black Recon allows crews to launch, operate, recover, and recharge up to three UAS without leaving their platform, reducing operator risk. Designed for vehicle integration, Black Recon allows crews to launch, operate, recover, and recharge up to three unmanned aerial systems without leaving their platform, reducing risk and accelerating decision-making. “Black Recon

OM Pharma to Unveil the Largest Multi-Country Real-World Evidence Study on Broncho‑Vaxom® (OM‑85) for RTI Prevention at EAACI 202614.6.2026 11:00:00 EEST | Press release

OM Pharma will reveal preliminary results from the REACH study at the European Academy of Allergy and Clinical Immunology (EAACI) Congress. REACH is the first and largest multi-country real-world evidence (RWE) study to date evaluating the impact of Broncho-Vaxom® in patients with recurrent respiratory tract infections (RTIs).1,2 The findings offer critical new clinical evidence of the therapy's effectiveness in everyday clinical practice. In a real-world cohort of 15,794 paediatric (aged >1 year), adolescent, adult and elderly patients in China, Italy, and Belgium, Broncho-Vaxom® was associated with reductions in RTI recurrence and healthcare utilisation at 12 and 24 months after treatment initiation, compared with the 12 months prior to starting the therapy.1 “The REACH real-world evidence study shows that Broncho-Vaxom® can significantly reduce infections requiring medical visits across age groups and co-morbidities,” said Anna Thomas, Chief Scientific Officer at OM Pharma. “Recurre

Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia13.6.2026 18:15:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced updated clinical data from two Phase 1 studies evaluating the safety, tolerability and efficacy of INCA033989, a first-in-class mutant calreticulin (mutCALR)-targeted monoclonal antibody, in patients with mutCALR-expressing myeloproliferative neoplasms (MPNs). INCA033989 demonstrated rapid, clinically meaningful responses and consistent molecular activity across both myelofibrosis (MF) and essential thrombocythemia (ET), with convergent evidence supporting the potential for disease modification. These findings are being presented in oral and poster presentations at the European Hematology Association (EHA) 2026 Congress in Stockholm, Sweden (Session: Myeloproliferative neoplasms – Clinical, Presentation numbers: S216, PS1983, PF884). “The data presented at EHA 2026 demonstrate clinically meaningful and consistent responses with INCA033989 across both myelofibrosis and essential thrombocythemia,” said Pablo J. Cagnoni, M.D., President of Incyte and G

Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi ® /Minjuvi ® ) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival13.6.2026 13:00:00 EEST | Press release

Incyte (Nasdaq:INCY) today announced positive results from the pivotal Phase 3 frontMIND trial evaluating the efficacy and safety of tafasitamab (Monjuvi®/Minjuvi®), a humanized Fc-modified cytolytic CD19-targeting monoclonal antibody, and lenalidomide added to R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone; Tafa-Len-R-CHOP) versus R-CHOP, the current standard of care, as a first-line treatment for adults with previously untreated diffuse large B-cell lymphoma (DLBCL) or high-grade B-cell lymphoma (HGBL). Eligible patients had an International Prognostic Index (IPI) score of 3-5, or, for patients ≤60 years of age, an age-adjusted IPI (aaIPI) of 2-3. These data are being highlighted in a prestigious Plenary Abstracts Session at the European Hematology Association (EHA) 2026 Congress, being held June 11 - 14, 2026, in Stockholm, Sweden (Abstract # S101. Plenary Abstract Session. June 13, 6:00 - 7:30 a.m. ET [12:00-1:30 p.m. CEST]). frontMIND results were als

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye